|
|
|
|
|
Highlights from the 2022 American Urological Association Annual Meeting (AUA) |
|
|
|
|
| Society of Urologic Oncology (SUO)
|
|
| Whitmore Lecture |
| Eila C. Skinner, MD |
| In a podium presentation at the 2022 Society of Urologic Oncology Meeting held in conjunction with the American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Eila Skinner presented the Whitmore Lecture, focusing on the question of what happened to continent urinary diversion in bladder cancer. |
|
|
|
|
|
| Is Cytoreductive Nephrectomy Dead or Alive in 2022?
|
| Daniel Shapiro, MD
|
| Daniel Shapiro discussing the role of cytoreductive nephrectomy in 2022. From a historical perspective, Dr. Shapiro notes that in a combined analysis of SWOG 8949 and EORTC 30947, the median overall survival for cytoreductive nephrectomy + IFN-alpha was 13 months and for IFN-alpha alone was 7.8 months (p = 0.001). Benefits of cytoreductive nephrectomy include improved survival, and can also be important for symptomatic/palliative reasons.
|
|
|
|
|
|
| Tips and Tricks in IVC Thrombectomy
|
| Stephen A. Boorjian, MD
|
| Stephen Boorjian presented on tips and tricks in inferior vena cava (IVC) thrombectomy. He began by highlighting the importance of the pre-operative imaging evaluation for patients with IVC thrombus. He suggested magnetic resonance imaging (MRI), and in particular MRV has notable value in assessing the height of the thrombus. Further, it allows evaluation and distinction between tumor thrombus and bland thrombus.
|
|
|
|
|
|
| Bladder Cancer: Non-Invasive I |
| Sequential Intravesical Gemcitabine and Docetaxel for BCG-Naïve High-Risk NMIBC |
| Ian McElree, BS, MS |
| Ian McElree discussed sequential intravesical gemcitabine + docetaxel for BCG-naïve high-risk non-muscle invasive bladder cancer (NMIBC). BCG is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor (TURBT) for high-risk NMIBC. However, production shortages have precluded BCG in many urologic practices, thus leading to urologists using gemcitabine + docetaxel in the BCG-naïve setting. |
|
|
|
|
|
| Surgical Technology & Simulation: Instrumentation & Technology |
| Single Port Robotic Urologic Surgery: Fewer Ports, Higher Costs |
| Mark Biebel, MD |
| The 2022 AUA Annual meeting held in New Orleans held a session covering contemporary surgical technologies in the field of Urology with a presentation by Mark Biebel on behalf of work from Brijesh Patel and colleagues investigating the cost comparison of surgery between the Da Vinci Xi and SP systems. This study was conducted as a retrospective cohort analysis of patients who underwent RAPN and RALP between January 2019 and January 2021. |
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer: Invasive IV |
| The Accuracy of (VI-RADS): An Updated Comprehensive Multi-Institutional, Multi-Readers Systematic Review and Meta-Analysis From Diagnostic Evidence Into Future Clinical Recommendations |
| Francesco Del Giudice, MD |
| In a podium presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Del Giudice presented the results of a systemic review and meta-analysis assessing the accuracy of the Vesical Imaging-Reporting and Data System. |
|
|
|
|
|
| Modeling the Contribution of Preoperative VI-RADS Score to Predict Final Pathologic Lymph-Nodes Involvement in Patients with MIBC Undergone Radical Cystectomy |
| Francesco Del Giudice, MD |
| Francesco Del Giudice presented results of work exploring the ability of the novel Vesical-Imaging Reporting and Data System (VI-RADS) to correlate with pathological nodal status at the time of radical cystectomy. VI-RADS was initially developed for the primary tumor staging of bladder cancer using multiparametric MRI. |
|
|
|
|
|
| Late-Breaking Abstract I |
| Interim Analysis: IV Vitamin C with Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients
|
| John Taylor, III, MD, MS
|
| In a podium presentation in the Late-Breaking Abstracts session at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Taylor presented interim results of a trial of intravenous (IV) vitamin C in combination with chemotherapy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin.
|
|
|
|
|
|
|
|
| AUA Guidelines Update: Renal Mass
|
| Steven Campbell, MD, Ph.D.
|
| The 2022 Annual Meeting of the American Urological Association was host to an AUA guidelines update session focused on renal masses, presented by Dr. Steven Campbell, MD, PhD. Dr. Campbell began his presentation by stating that the primary focus of these guidelines is clinically localized renal masses suspicious for cancer in adults, including solid enhancing renal tumor and Bosniak 3 and 4 complex cystic renal masses.
|
|
|
|
|
|
| Kidney Cancer: Localized: Surgical Therapy I
|
|
| Race Based Equations for Estimating Kidney Function contribute to Racial Disparities In Partial Nephrectomy Utilization Among Black Patients with Kidney Tumors
|
| Nour Abdallah, MD
|
| Nour Abdallah gave a poster presentation on the disparities that may arise between races and the types of surgeries they receive. Specifically, Abdallah et. Al. found that compared to other races, black Americans receive a higher number of radical nephrectomies than partial nephrectomies. This is a major problem due to black Americans being at higher risk of comorbidities and being diagnosed with chronic kidney disease (CKD). The team sought to out to find a reason behind these disparities.
|
|
|
|
|
|
| Uroradiology I |
| Development of a Urinary Tract Atlas Using Convolutional Neural Networks
|
| Katherine Fischer, MD
|
| Artificial Intelligence (AI) was a popular topic at the first uroradiology moderated poster session of the 2022 AUA Annual Meeting. Katherine Fischer, MD presented research on training a convolutional neural network (CNN) – a type of AI framework typically used for imaging-based studies – to identify and highlight kidneys, ureters, and bladder on CT scans. This study was supported by NIH funding and in part by 2021-2022 Urology Care Foundation Research Scholar Award Program.
|
|
|
|
|
|
 |
